Buchumschlag

Ruxolitinib is effective in the treatment of a patient with refractory T-ALL

T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic bloo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jaramillo Segura, Sonia (VerfasserIn) , Hennemann, Hannah Mai (VerfasserIn) , Horak, Peter (VerfasserIn) , Teleanu, Maria-Veronica (VerfasserIn) , Heilig, Christoph E. (VerfasserIn) , Hutter, Barbara (VerfasserIn) , Stenzinger, Albrecht (VerfasserIn) , Glimm, Hanno (VerfasserIn) , Goeppert, Benjamin (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Fröhling, Stefan (VerfasserIn) , Schönland, Stefan (VerfasserIn) , Schlenk, Richard Friedrich (VerfasserIn)
Dokumenttyp: Article (Journal) Editorial
Sprache:Englisch
Veröffentlicht: 2021
In: eJHaem
Year: 2021, Jahrgang: 2, Heft: 1, Pages: 139-142
ISSN:2688-6146
DOI:10.1002/jha2.143
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/jha2.143
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jha2.143
Volltext
Verfasserangaben:Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutter, Albrecht Stenzinger, Hanno Glimm, Benjamin Goeppert, Carsten Müller-Tidow, Stefan Fröhling, Stefan Schönland, Richard F. Schlenk
Beschreibung
Zusammenfassung:T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T-ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3-mutated refractory T-ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T-ALL.
Beschreibung:First published: 04 December 2020
Gesehen am 07.09.2021
Beschreibung:Online Resource
ISSN:2688-6146
DOI:10.1002/jha2.143

Ähnliche Einträge